Syngeneic, pluripotent Lin − Sca1 + bone marrow stem cells (SC), transferred to mice with experimental autoimmune encephalomyelitis, a model of multiple sclerosis, enhanced recovery, prevented relapses and promoted myelin repair. SC-treated mice showed elevated interferon-γ production and induction of indoleamine 2,3-dioxygenase (IDO) in CD11c + dendritic cells (DC). IDO induction was specific since in the presence of IDO-producing CD11c + DC, PLP stimulated T cell proliferation was inhibited and the IDO-inhibitor, 1-MT, abrogated the SC effect. Relapse prevention during chronic disease correlated with decreased responsiveness to PLP [178][179][180][181][182][183][184][185][186][187][188][189][190][191] . Thus, pluripotent SC induce IDO in DC leading to inhibition of antigen reactivity and spreading in EAE.
Introduction
Multiple sclerosis (MS) is a chronic inflammatory demyelinating condition of the human central nervous system (CNS), characterized by recurrent episodes of immune-mediated demyelination and axonal loss (Frohman et al., 2006) . Of recently proposed therapeutic strategies, transplantation of myelin-forming precursor cells or stem cells (SC) to the site of injury has generated both interest and reservations (Lassmann, 2005; Pluchino and Martino, 2005) . In this regard, it is recognized that limitations like the multifocal nature of CNS lesions in MS and the restriction of cell migration within demyelinated plaques pose serious challenges to the SC approach.
Stem cells, a potential source of cells for all tissues due to their ability to differentiate into almost any cell type, develop through a series of stages which finally give rise to lineage specific cell types. In mice, lineage negative (Lin − ) cells expressing the Sca1 molecule (Lin − Sca1 + ) represent a pluripotent population of bone marrow SC (BMSC) depleted of mature hematopoietic precursors and enriched in mesenchymal SC (Kucia et al., 2005; Vogel et al., 2003) . With further development, expression of Sca1 is lost and SC acquire tissue specific markers (Zuba-Surma et al., 2006) . Mesenchymal (or stromal) SC are capable of differentiating into myogenic, osteogenic, chondrogenic and adipogenic cell lineages (Seshi et al., 2000; Pittenger et al., 1999) . In murine transplant models, mesenchymal SC can also give rise to non-mesenchymal elements, including liver (Petersen et al., 1999 ), neuronal (Brazelton et al., 2000 and glial cells (Kopen et al., 1999) . It has been suggested that mesenchymal bone marrow stem cells might provide a non-embryonic or non-fetal source of SC suitable for cell replacement in treatment of CNS disorders (Alhadlaq and Mao, 2004) .
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